A better method is nuclear medicine imaging using radiolabeled amines which rapidly cross the normal blood brain barrier. Perfusion defects can be detected early using this technique since the scans mapping re gional blood ?ow immediately display damage in pa tients who suffer strokes.
Two radioiodinated brain imaging amines that have been developed are N-isopropyl-p-iodoamphetamine (IMP) and N,N,N'-trimethyl-N'-(2-hydroxyl-3-methyl 5-iodobenzyl)-1,3-propanediamine (HIPDM). IMP has shown an advantage over HIPDM of having almost twice the amount of activity in the brain ?ve minutes after administration, leading to clearer images. It also clears the lungs faster resulting in better images since the scattering of high energy photons from the lung region is less. This minimizes the degradation of the brain image. These compounds are prepared by ?rst synthesizing a halogenated precursor and then labeling by isotopic exchange. However, there are limitations to this synthetic approach. The speci?c activity is gener ally low due to presence of unlabeled starting material and the exchange reaction is slow and must be pre formed at high temperatures. It is therefore necessary to provide compounds for efficient imaging of cerebral blood flow that are easy to'make and result in clear images. ' SUMMARY OF THE INVENTION In view of the above mentioned need it is an object of this invention to provide compounds for imaging cere bral blood ?ow in warm blooded animals that have high speci?c activity in the brain as compared with other locations in the body.
It is another object of this invention to provide brain imaging compounds that can be made without resulting in dilution of the imaging effect by unlabeled starting material.
It is another object of this invention to provide brain imaging compounds that can be made by radi ohalogenation at low temperatures.
It is a further object of this invention to provide brain imaging compounds that can be used in conjunction with nuclear scanning technology to render a distinct image of the brain. Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will be come apparent to those skilled in the art upon examina tion of the following or may be learned by practice of the invention. The objects and advantages of the inven tion may be realized and attained by means of the instru mentalities and combinations particularly pointed out in the appended claims.
To achieve the foregoing and other objects and in accordance with the purpose of the present invention, as embodied and broadly described herein, the composi tion of matter of this invention may comprise radi ohalogenated thienylmonoamines having the structure [k #X I S wherein *X is a radiohalogen and R is H or alkyl or aryl.
The invention is also a radiopharmaceutical kit com prising 2-(2-aminopropyl)-5-trimethylstannylthiophene, starting material for the unsubstituted imaging com pound which can be radiohalogenated. The invention is also a kit comprising 2-(2-aminopropyl)-S-dihydrox yboranethiophene. Treatment of either of these com pounds by iodestannylation with sodium radiohalide and N-chlorosuccinimide produces 2-(2-aminopropyl)
5-radiohalothiophene.
The invention is also a process for radioimaging wherein a compound as described above is mixed with a suitable administering medium. This mixture is in jected into a warm blooded animal, allowed to cross the blood-brain barrier and .a radioimage is recorded using standard radioimaging techniques.
The advantages of the invention include a simple synthesis route and a compound which is less diluted with nonradioactive halogen than the compounds of the prior art resulting in either a clearer image or a lower dose, depending on one's objective.
BRIEF DESCRIPTION OF THE DRAWING
The FIGURE represent a series of reactions'for mak ing the various compounds discussed and claimed in the application.
DETAILED DESCRIPTION OF THE
PREFERRRED EMBODIMENT Prior art brain imaging compounds IMP and HIPDM were routinely prepared by making a nonradioactive halogenated precursor and then substituting the non radioactive halogen with a radiohalogen by isotopic exchange. The problems with this approach were that the speci?c activity was normally low due to the pres ence of unlabeled starting material and the isotopic exchange reaction was slow and had to be preformed at high temperature. A promising labeling technique is halodemetallation which quickly gives high radiochem ical yields at low temperatures. Accordingly, the use of thiophene 2-substituted tissue specific agents are of interest because the reactive 5-position of the thiophene ring undergoes facile coupling to a variety of metals, as well as direct reaction with halogen.
The radiopharmaceuticals are prepared by first pre paring intermediates which are then radiohalogenated to form the product. To prepare these intermediates, as structurally illustrated in the FIGURE, thiophene-2 carboxaldehyde (1), which can be acquired from a chemically supplier, is treated in the presence of acetic acid and sodium acetate with nitroethane to give l-(2 thienyl)-2-nitropropene (2), Reaction I. Although acetic acid and ammonium acetate are present in the preferred embodiment, other combinations such as nitroethane and ammonium acetate, can also be used instead. This compound is then reduced with B2H6 to form 2-(2 aminopropyl)-thiophene (3), Reaction II. Lithiation of (3) with n-butyl lithium followed by treatment with trimethyl tin chloride gave an intermediate compound, 2-(2-aminopropyl)-5-trimethylstannylthiophene (4), Re action III. Halogenation with sodium radiohalide and N-chlorosuccinimide produces 2-(2-aminopropyl)-5 radiohalothiophene (6), Reaction Va. Therefore, com pound (4) can be sold as a kit comprising the starting material which is then radiohalogenated at the location where the radiopharmaceutical is to be administered.
Another intermediate can also be prepared that will also undergo radiohalogenation at the location of ad ministration. Compound (3) is treated with n-butyl lith ium and then B(OC3H7)3 to form the [hydrox yboride](5), Reaction IV. This compound is the radi ohalogenated using sodium radiohalide and N chlorosuccinimide, Reaction Vb. Thus, the compound (5) can also comprise a kit that is used as starting mate rial to form product (6).
In addition to the unsubstituted amines, substituted amines can also be made. Treatment of (3) Key intermediates that can also comprise kits are com pounds (9) and (10). EXAMPLE The Table shows the tissue distribution of two radi ohalogens in Fisher rats. Bromine-82 labeled compound corresponding to 7 showed good brain uptake and re tention in rats. The second model agent, iodine-125 compound corresponding to 6 showed high brain up take and good retention with high brain-to-blood ratios. The compounds are used by mixing with a suitable administering medium, administering the mixture to a warm blooded animal by intravenous injection, allow ing the mixture to cross the blood-brain barrier and recording a radioimage using radioimaging techniques.
The amount of compound to be used can easily be de termined by persons of ordinary skill in the art. injecting an effective amount of said mixture into a warm blooded animal; allowing said mixture to cross the blood-brain barrier;
and recording a radioimage.
8. The process of claim 7 wherein said radi ohalogenated thienylmonoamine comprises A 11X S 9. The process of claim 7 wherein said radiohalogen is selected from the group I-l22, L123, L125, Br-75 and 10. The process of claim 8 wherein said radiohalogen is selected from the group I-l22, I-l23, I-l25, Br-75 and 11. The process of claim 9 wherein said radiohalogen is selected from the group I-l25 and Br-82 and said R is selected from the group H.
12. The process of claim 10 wherein said radiohalo gen is selected from the group I-125 and Br-82.
